Zacks Investment Research Lowers Urovant Sciences (NASDAQ:UROV) to Sell

Zacks Investment Research cut shares of Urovant Sciences (NASDAQ:UROV) from a hold rating to a sell rating in a report issued on Saturday, Zacks.com reports.

According to Zacks, “Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company’s product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London, United Kingdom. “

UROV has been the topic of a number of other reports. HC Wainwright reduced their price target on shares of Urovant Sciences from $33.00 to $28.00 and set a buy rating on the stock in a research note on Friday, June 19th. BidaskClub upgraded shares of Urovant Sciences from a sell rating to a hold rating in a research note on Wednesday, June 3rd. Finally, ValuEngine upgraded shares of Urovant Sciences from a hold rating to a buy rating in a research report on Thursday, April 2nd.

UROV opened at $10.19 on Friday. The company’s 50 day moving average is $10.06 and its 200-day moving average is $11.14. Urovant Sciences has a 1-year low of $6.55 and a 1-year high of $15.98. The company has a current ratio of 1.89, a quick ratio of 1.89 and a debt-to-equity ratio of 1.83. The company has a market cap of $316.31 million, a P/E ratio of -2.11 and a beta of 1.45.

Urovant Sciences (NASDAQ:UROV) last posted its quarterly earnings results on Thursday, June 18th. The company reported ($1.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.43). On average, equities analysts forecast that Urovant Sciences will post -6.88 EPS for the current year.

A number of large investors have recently bought and sold shares of the stock. Perceptive Advisors LLC boosted its position in Urovant Sciences by 7.1% during the 4th quarter. Perceptive Advisors LLC now owns 2,406,931 shares of the company’s stock worth $37,331,000 after buying an additional 160,384 shares during the period. FMR LLC boosted its position in Urovant Sciences by 28.4% during the 1st quarter. FMR LLC now owns 1,710,836 shares of the company’s stock worth $17,194,000 after buying an additional 378,135 shares during the period. Alyeska Investment Group L.P. boosted its position in Urovant Sciences by 171.9% during the 1st quarter. Alyeska Investment Group L.P. now owns 483,168 shares of the company’s stock worth $4,455,000 after buying an additional 305,437 shares during the period. BlackRock Inc. raised its holdings in Urovant Sciences by 5.2% during the 1st quarter. BlackRock Inc. now owns 305,489 shares of the company’s stock worth $2,817,000 after purchasing an additional 15,219 shares during the last quarter. Finally, First Manhattan Co. bought a new position in Urovant Sciences during the 1st quarter worth approximately $2,114,000. Institutional investors and hedge funds own 23.81% of the company’s stock.

About Urovant Sciences

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

Read More: What’s a Black Swan?

Get a free copy of the Zacks research report on Urovant Sciences (UROV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.